CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to BioTime, Inc.	$ (46,991)	$ (36,412)	$ (43,883)
Net loss allocable to non-controlling interest	(11,143)	(7,367)	(9,026)
Gain on sale of assets	(3,694)	0	0
BioTime's share of losses of equity method investment	35	0	0
Adjustments to reconcile net loss attributable to BioTime, Inc. to net cash used in operating activities:
Acquired in-process research and development	0	0	17,459
Depreciation expense	1,078	1,051	657
Amortization of intangible assets	5,256	7,360	3,296
Amortization of deferred consulting fees	0	19	65
Amortization of deferred license fees	114	110	109
Amortization of deferred license, royalty and subscription revenues	102	(1)	(915)
Amortization of prepaid rent in common stock	63	85	85
Stock-based compensation	11,050	4,455	3,218
Subsidiary common stock issued in lieu of cash for services	486	0	0
Amortization of discount on related party convertible debt	245	56	0
Loss/(gain) on sale or write-off of equipment	1	9	(5)
Write-off for uncollectible receivables	0	(16)	0
Contingently issuable subsidiary warrants in lieu of investor relations expenses	65	0	0
Deferred income tax benefit	(4,516)	(7,376)	(3,281)
Changes in operating assets and liabilities:
Accounts receivable, net	(248)	(74)	(181)
Grant receivable	168	11	560
Inventory	(75)	(87)	(123)
Prepaid expenses and other current assets	(1,458)	(86)	428
Other long-term assets	(100)	0	(15)
Accounts payable and accrued liabilities	1,673	(470)	2,142
Accrued interest on related party convertible debt	19	4	0
Other long-term liabilities	(20)	(160)	(58)
Deferred grant income	2,513	0	0
Deferred rent liabilities	61	61	(22)
Deferred revenues	772	(26)	(19)
Net cash used in operating activities	(44,544)	(38,854)	(29,509)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment	(1,241)	(483)	(2,277)
Payments on construction in progress	(4,093)	(219)	0
Purchase of foreign available-for-sale securities	(748)	0	0
Payment for Ascendance equity method investment	(500)	0	0
Payment of transaction fees to Geron	0	0	(978)
Payment of syndication fees incurred	0	0	(376)
Proceeds from the sale of equipment	0	9	31
Security deposit paid, net	(859)	(315)	(65)
Cash used in investing activities	(7,441)	(1,008)	(3,665)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercises of stock options	621	219	46
Proceeds from sale of preferred stock	0	3,500	0
Proceeds from issuance of common shares	34,123	44,150	25,939
Fees paid on sale of common shares	0	(323)	(818)
Proceeds from exercises of warrants	20	0	0
Proceeds from exercise of subsidiary stock options	33	8	0
Proceeds from sale of treasury shares	1,347	0	0
Proceeds from exercise of subsidiary warrants	11,700	0	0
Proceeds from sale of treasury shares and issuance of subsidiary warrants	0	15,156	3,842
Proceeds from sale of subsidiary common shares	13,639	468	5,255
Fees paid on sale of subsidiary common shares	(693)	0	0
Reimbursement from landlord on construction in progress	3,789	0	0
Proceeds from issuance of related party convertible debt	255	471	0
Repayment of capital lease obligation	(59)	(26)	0
Net cash provided by financing activities	64,775	63,623	34,264
Effect of exchange rate changes on cash and cash equivalents	(48)	230	56
NET INCREASE IN CASH AND CASH EQUIVALENTS	12,742	23,991	1,146
CASH AND CASH EQUIVALENTS:
At beginning of year	29,487	5,496	4,350
At end of year	42,229	29,487	5,496
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during year for interest	119	91	3
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES :
Common shares issued to Cell Cure in exchange for Cell Cure shares	0	0	3,500
Common shares issued for consulting services	0	0	173
Common shares issued for rent	0	0	254
Intangible assets acquired from Geron	0	0	29,017
Common shares issued to Asterias upon consummation of Asset Contribution Agreement (Treasury shares)	0	0	34,985
Employee options exercised with common stock	0	973	0
Capital expenditure funded by capital lease borrowing	34	115	0
Construction in progress in accounts payable and accrued expenses	524	186	0
Landlord receivable	(567)	(378)	0
Lease liability	4,400	378	0
Warrants issued to Asterias upon consummation of Asset Contribution Agreement	0	0	18,276
Equity method investment in Ascendance in exchange for assets	$ 4,706	$ 0	$ 0